2009年，欧洲白血病国际联盟的专家认为三氧化二砷是“治疗APL最有生物活性的单个药物”（“the most biologically active single drug in APL”）（Sanz et al.，2009)。

 

     同年，美国白血病专家认为三氧化二砷被是治疗APL患者最有效的单个药物（“the single most active agent in patients with APL”）（Tallman and Altman, 2009)。

 

     三氧化二砷和全反型维甲酸合并用药可能“不久的将来在多数，如果不是全部，APL患者中替代常规疗法” （“replace conventional approaches for most, if not all, patients in the very near future”）（Tallman and Altman, 2009)。

 

     近年的研究更见证了世界上广泛接受三氧化二砷治疗APL(Sanz and Lo-Coco 2011)，并继续有更多证据表明三氧化二砷对新诊断的和复发的APL都有治疗作用 (Estey, 2011; Powell et al., 2011)。

 

     也就是说，对于APL最重要的药物，其关键发现者，却默默无闻。

 

     Estey EH (2011) Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center. Journal of Clinical Oncology 29:2743-2746.

     Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman and Larson RA (2010). Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116:3751-3757.

     Sanz A, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, and Lo-Coco F (2009). Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875-1891.

     Sanz MA and Lo-Coco F (2011). Modern approaches to treating acute promyelocytic leukemia. Journal of Clinical Oncology 29:495-503.

     Tallman MS and Altman JK (2009). How I treat acute promyelocytic leukemia. Blood 114:51260-35.